Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue (2018 - 2021)

Fulcrum Therapeutics (FULC) has 4 years of Non-Current Deffered Revenue data on record, last reported at $1.7 million in Q4 2021.

  • On a quarterly basis, Non-Current Deffered Revenue fell 43.45% to $1.7 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.7 million, a 43.45% decrease, with the full-year FY2021 number at $1.7 million, down 43.45% from a year prior.
  • Non-Current Deffered Revenue reached $1.7 million in Q4 2021 per FULC's latest filing, up from $1.6 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for FULC hit a ceiling of $6.0 million in Q3 2020 and a floor of $1.4 million in Q4 2018.
  • A 4-year average of $2.1 million and a median of $1.6 million in 2020 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 290.64% in 2020, then crashed 72.47% in 2021.
  • Tracing FULC's Non-Current Deffered Revenue over 4 years: stood at $1.4 million in 2018, then rose by 11.2% to $1.6 million in 2019, then soared by 90.57% to $3.0 million in 2020, then crashed by 43.45% to $1.7 million in 2021.
  • Business Quant data shows Non-Current Deffered Revenue for FULC at $1.7 million in Q4 2021, $1.6 million in Q3 2021, and $1.7 million in Q2 2021.